333 related articles for article (PubMed ID: 12009017)
21. G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.
Katsumata N; Kuno T; Miyazaki S; Mikami S; Nagashima-Miyokawa A; Nimura A; Horikawa R; Tanaka T
Endocr J; 1998 Apr; 45 Suppl():S171-4. PubMed ID: 9790257
[TBL] [Abstract][Full Text] [Related]
22. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
23. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models.
Kannan K; Givol D
IUBMB Life; 2000 Mar; 49(3):197-205. PubMed ID: 10868910
[TBL] [Abstract][Full Text] [Related]
24. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
25. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
Monsonego-Ornan E; Adar R; Feferman T; Segev O; Yayon A
Mol Cell Biol; 2000 Jan; 20(2):516-22. PubMed ID: 10611230
[TBL] [Abstract][Full Text] [Related]
26. FGFR3 isoforms have distinct functions in the regulation of growth and cell morphology.
Shimizu A; Takashima Y; Kurokawa-Seo M
Biochem Biophys Res Commun; 2002 Jan; 290(1):113-20. PubMed ID: 11779141
[TBL] [Abstract][Full Text] [Related]
27. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
28. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
29. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
Iwata T; Li CL; Deng CX; Francomano CA
Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.
Murgue B; Tsunekawa S; Rosenberg I; deBeaumont M; Podolsky DK
Cancer Res; 1994 Oct; 54(19):5206-11. PubMed ID: 7923141
[TBL] [Abstract][Full Text] [Related]
31. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
[TBL] [Abstract][Full Text] [Related]
32. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I.
Tavormina PL; Rimoin DL; Cohn DH; Zhu YZ; Shiang R; Wasmuth JJ
Hum Mol Genet; 1995 Nov; 4(11):2175-7. PubMed ID: 8589699
[No Abstract] [Full Text] [Related]
33. Fibroblast growth factor receptor 3 and the human chondrodysplasias.
Horton WA
Curr Opin Pediatr; 1997 Aug; 9(4):437-42. PubMed ID: 9300204
[TBL] [Abstract][Full Text] [Related]
34. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1.
Rousseau F; Saugier P; Le Merrer M; Munnich A; Delezoide AL; Maroteaux P; Bonaventure J; Narcy F; Sanak M
Nat Genet; 1995 May; 10(1):11-2. PubMed ID: 7647778
[No Abstract] [Full Text] [Related]
35. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.
Thompson LM; Raffioni S; Wasmuth JJ; Bradshaw RA
Mol Cell Biol; 1997 Jul; 17(7):4169-77. PubMed ID: 9199352
[TBL] [Abstract][Full Text] [Related]
36. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
Tavormina PL; Shiang R; Thompson LM; Zhu YZ; Wilkin DJ; Lachman RS; Wilcox WR; Rimoin DL; Cohn DH; Wasmuth JJ
Nat Genet; 1995 Mar; 9(3):321-8. PubMed ID: 7773297
[TBL] [Abstract][Full Text] [Related]
37. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
38. Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.
Kouhara H; Kurebayashi S; Hashimoto K; Kasayama S; Koga M; Kishimoto T; Sato B
Oncogene; 1995 Jun; 10(12):2315-22. PubMed ID: 7784079
[TBL] [Abstract][Full Text] [Related]
39. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.
L'Hôte CG; Knowles MA
Exp Cell Res; 2005 Apr; 304(2):417-31. PubMed ID: 15748888
[TBL] [Abstract][Full Text] [Related]
40. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
